Caucasian Ethnicity, but Not Treatment Cessation Is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion

Autor: Bettina E. Hansen, Stijn Van Hees, Frederik Nevens, Harry L.A. Janssen, Suzanne Bourgeois, David Wong, Thomas Sersté, Heng Chi, Sven Francque, Hans Van Vlierberghe, Christophe Moreno, Dirk Sprengers, Thomas Vanwolleghem
Přispěvatelé: Gastroenterology & Hepatology
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Male
HBsAg
Ethnic group
lcsh:QR1-502
HBsAg seroclearance
THERAPY
Gastroenterology
lcsh:Microbiology
0302 clinical medicine
Medicine and Health Sciences
030212 general & internal medicine
Pathologie maladies infectieuses
LONG-TERM TREATMENT
Hazard ratio
virus diseases
Nucleosides
Middle Aged
Treatment Outcome
Infectious Diseases
HBeAg
Seroconversion
Cohort
ethnicity
Female
030211 gastroenterology & hepatology
CHRONIC HEPATITIS-B
Cohort study
Adult
CLINICAL-OUTCOMES
Hepatitis B virus
medicine.medical_specialty
Genotype
Antiviral Agents
Article
White People
03 medical and health sciences
Hepatitis B
Chronic
Immune system
Virology
Internal medicine
medicine
Humans
COHORT
chronic hepatitis B
Proportional Hazards Models
Retrospective Studies
SURFACE-ANTIGEN SEROCLEARANCE
Hepatitis B Surface Antigens
business.industry
treatment cessation
digestive system diseases
Withholding Treatment
DNA
Viral
Sciences pharmaceutiques
Human medicine
business
Zdroj: Viruses, Vol 11, Iss 8, p 687 (2019)
Viruses
VIRUSES-BASEL
Viruses-Basel, 11(8):687. Multidisciplinary Digital Publishing Institute (MDPI)
Volume 11
Issue 8
Viruses, 11 (8
ISSN: 1999-4915
Popis: It is well appreciated that ethnicity influences the natural history and immune responses during a chronic hepatitis B infection. In this study, we explore the effect of ethnicity and treatment cessation on Hepatitis B surface Antigen (HBsAg) seroclearance in patients with Nucleos(t)ide Analogue (NA)-induced Hepatitis B e Antigen (HBeAg) seroconversion. We performed a multi-ethnic, multicentric observational cohort study. The analyzed cohort consisted of 178 mono-infected, predominantly male (75.3%) chronic hepatitis B patients of mixed ethnicity (44.4% Asians, 48.9% Caucasians) with nucleos(t)ide analogue-induced HBeAg seroconversion. Treatment was withdrawn in 105 patients and continued in 73, leading to HBsAg loss in 14 patients off- and 16 patients on-treatment, respectively. Overall, HBsAg loss rates were not affected by treatment cessation (hazard ratio 1.45, p = 0.372), regardless of consolidation treatment duration. Caucasian ethnicity was associated with an increased chance of HBsAg loss (hazard ratio 6.70, p = 0.001), but hepatitis B virus genotype was not (p = 0.812). In conclusion, ethnicity is the most important determinant for HBsAg loss after NA-induced HBeAg seroconversion, with up to six-fold higher HBsAg loss rates in Caucasians compared to Asians, irrespective of treatment cessation and consolidation treatment duration.
SCOPUS: ar.j
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje